TW200716094A - Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor - Google Patents

Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Info

Publication number: TW200716094A
Authority: TW; Taiwan
Prior art keywords: methods; pharmaceutical compositions; aromatase inhibitor; combination; phenyl
Prior art date: 2005-04-25

Application number

TW095114529A

Other languages

English (en)

Chinese (zh)

Inventor

Madelyn Curto

Melanie Sisson

Andrew George Lee

David Duane Thompson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-25

Filing date

2006-04-24

Publication date

2007-05-01

2006-04-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-05-01 Publication of TW200716094A publication Critical patent/TW200716094A/zh

Links

229940122815 Aromatase inhibitor Drugs 0.000 title abstract 3
239000003886 aromatase inhibitor Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
239000000333 selective estrogen receptor modulator Substances 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 3
239000000651 prodrug Substances 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
GGPPBTSXFROGAE-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile Chemical compound C1=CC(Br)=CC=C1CN(N1C=NN=C1)C1=CC=C(C#N)C=C1 GGPPBTSXFROGAE-UHFFFAOYSA-N 0.000 abstract 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
229960003437 aminoglutethimide Drugs 0.000 abstract 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 abstract 1
229960002932 anastrozole Drugs 0.000 abstract 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 abstract 1
229950004810 atamestane Drugs 0.000 abstract 1
229960000255 exemestane Drugs 0.000 abstract 1
229950011548 fadrozole Drugs 0.000 abstract 1
SLJZVZKQYSKYNV-ZWKOTPCHSA-N finrozole Chemical compound C([C@H](O)[C@@H](C=1C=CC(=CC=1)C#N)N1N=CN=C1)C1=CC=C(F)C=C1 SLJZVZKQYSKYNV-ZWKOTPCHSA-N 0.000 abstract 1
229950001083 finrozole Drugs 0.000 abstract 1
229960004421 formestane Drugs 0.000 abstract 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 1
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
229960003881 letrozole Drugs 0.000 abstract 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
229960001771 vorozole Drugs 0.000 abstract 1
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095114529A 2005-04-25 2006-04-24 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor TW200716094A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US67480705P	2005-04-25	2005-04-25

Publications (1)

Publication Number	Publication Date
TW200716094A true TW200716094A (en)	2007-05-01

Family

ID=36693972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095114529A TW200716094A (en)	2005-04-25	2006-04-24	Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor

Country Status (6)

Country	Link
EP (1)	EP1937251A2 (fr)
JP (1)	JP2006306872A (fr)
AR (1)	AR054258A1 (fr)
CA (1)	CA2605796A1 (fr)
TW (1)	TW200716094A (fr)
WO (1)	WO2006114702A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20090029237A (ko)	2006-06-02	2009-03-20	피어 트리 파머슈티칼스 인코포레이티드	위축성 질염을 치료하는 방법
EP2070943A1 (fr) *	2007-12-14	2009-06-17	Crystal Pharma, S.A.	Procédé de préparation des 6-Alkylidenandrost-1,4-dien-3-ones
JP5777163B2 (ja) *	2009-07-03	2015-09-09	国立研究開発法人理化学研究所	Ｐｅｔ用標識化合物
JP6280501B2 (ja) *	2011-09-08	2018-02-14	メレオバイオファーマ２リミテッド	性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用
CA3022377A1 (fr)	2016-04-29	2017-11-02	Board Of Regents, The University Of Texas System	Mesure ciblee de l'activite transcriptionnelle liee aux recepteurs hormonaux

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
AR034142A1 (es) *	2000-09-08	2004-02-04	Sloan Kettering Inst Cancer	Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
EP1317270A1 (fr) *	2000-09-08	2003-06-11	Pharmacia Italia S.p.A.	Utilisation d'exemestane comme agent de chimio-prevention
WO2003017973A1 (fr) *	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet
EP1435967A2 (fr) *	2001-10-10	2004-07-14	Pharmacia Italia S.p.A.	Procedes de prevention et de traitement de la deperdition osseuse avec des composes steroides
TW200526206A (en) *	2004-01-13	2005-08-16	Wyeth Corp	Treatment of aromatase inhibitor therapy-related osteoporosis
CA2586844A1 (fr) *	2004-11-04	2006-05-11	Pfizer Products Inc.	Anticorps ctla-4 et inhibiteur de l'aromatase ou traitement combine du cancer du sein

2006
- 2006-04-13 EP EP06744583A patent/EP1937251A2/fr not_active Withdrawn
- 2006-04-13 WO PCT/IB2006/001040 patent/WO2006114702A2/fr not_active Ceased
- 2006-04-13 CA CA002605796A patent/CA2605796A1/fr not_active Abandoned
- 2006-04-24 AR AR20060101616A patent/AR054258A1/es not_active Application Discontinuation
- 2006-04-24 JP JP2006118713A patent/JP2006306872A/ja active Pending
- 2006-04-24 TW TW095114529A patent/TW200716094A/zh unknown

Also Published As

Publication number	Publication date
AR054258A1 (es)	2007-06-13
CA2605796A1 (fr)	2006-11-02
WO2006114702A2 (fr)	2006-11-02
EP1937251A2 (fr)	2008-07-02
JP2006306872A (ja)	2006-11-09
WO2006114702A3 (fr)	2007-01-04

Publication	Publication Date	Title
ATE504565T1 (de)	2011-04-15	Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
JP2010521483A5 (fr)	2011-04-14
CY1109860T1 (el)	2014-09-10	Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
GEP20115213B (en)	2011-05-10	Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NZ593593A (en)	2013-11-29	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW200626148A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
PH12021551290A1 (en)	2022-03-28	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
TW200626138A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
TW200626592A (en)	2006-08-01	Heterocyclic derivatives and their use as therapeutic agents
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
NO20060981L (no)	2006-05-02	Pyridazinderivater og deres anvendelse som terapeutiske midler
UA86957C2 (ru)	2009-06-10	Производные азепиноиндола в качестве фармацевтического средства
UA84146C2 (ru)	2008-09-25	Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
RU2009118254A (ru)	2010-11-27	Фенилацетамиды в качестве ингибиторов протеинкиназ
CA2484188A1 (fr)	2003-11-06	Antagonistes du recepteur tachykinine
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20054905L (no)	2006-01-25	2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
CA2409741A1 (fr)	2001-12-06	Inhibiteurs de production de tnf-.alpha.
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
ATE384058T1 (de)	2008-02-15	Thiazolderivate
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
WO2005030187A3 (fr)	2005-06-23	Iloprost en polytherapies pour le traitement de l'hypertension arterielle pulmonaire
MXPA06003122A (es)	2006-05-31	Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.